First patient enrolled in the DISCO RADIAL study
Terumo Europe N.V., a leading medical device company, announces the launch of a new randomized clinical trial: the DIStal vs COnventional RADIAL access trial (DISCO RADIAL). The trial compares the novel distal radial access with conventional radial access approach, in terms of radial occlusion rates (RAO) at discharge.
Transradial approach is the preferred vascular access for coronary angiography and interventions. Recently, the distal radial artery from the anatomical snuffbox on the dorsal side of the hand ("distal TRA" or "snuffbox access") has emerged as an alternative access to the conventional forearm radial artery for coronary angiography and interventions.
DISCO RADIAL is the first large international randomized study designed to investigate the benefits of distal radial access over conventional radial access approach. The study plans to enrol 1300 patients, in approximately 13 centers in Europe and Japan. The patients will be randomly assigned to one of the two access groups.
DISCO RADIAL aims to generate clinical evidence on the potential benefits of this novel distal access approach over the conventional radial approach, and to support the use of the distal radial approach as an alternative to the conventional radial approach.
Principal investigator Dr Saito, Interventional Cardiologist from Shonan Kamakura General Hospital, Japan, commented: 'The radial approach is a small world and just one of the access methods. However, its impact on the clinical field has been proven potent and significant. Everybody was thinking we will never have anything novel in this small world. However, unexpectedly it was not true. The distal radial approach is truly novel, and nobody has evidence yet proving its advantage over the conventional radial approach. As the group of physicians working in this field, we have the responsibility to show its efficacy. That is the reason to initiate the trial.'
Principal investigator Dr Aminian, Interventional Cardiologist from Centre Hospitalier Universitaire de Charleroi, Belgium, said: 'This novel access has raised great enthusiasm among the radial community, despite the paucity of clinical evidence supporting its use. Beyond potential advantages related to improved operator/patient comfort, easier and shorter haemostasis, an important feature of this technique is a puncture distal to the superficial palmar arch. Distal TRA has the potential to maintain antegrade flow in the forearm radial artery during haemostatic compression, reducing thereby the risk of retrograde thrombus formation in the forearm radial artery and therefore the risk of RAO. The current available data on distal TRA is limited to relatively small prospective and retrospective case series looking primarily at the feasibility and success rates with this approach. By assessing the potential benefit and limitations of this alternative access, DISCO RADIAL will have an important clinical impact for radial operators.'
Dr Christophe Giot, Chief Medical Officer, Terumo Europe, commented that this study will generate clinical evidence for this novel distal access approach, and reflects Terumo's commitment to evidence based clinical practice and to the improvement of patients' healthcare.
Enrolment is expected to be completed within one year, and results are expected to be available in 2021. Terumo, the pioneer in transradial access products, is sponsoring this new study.
– End –
For more information Name: Irene Barriocanal Title: Clinical Project & Team manager, EMCD, Terumo Europe Tel: +32 16381380 EMAIL: Irene.Barriocanal@terumo-europe.com
About Terumo Europe NV
Terumo Europe, founded in 1971, is a core player in the EMEA healthcare market by providing best in class quality medical products and services. We are a strong actor of the Terumo Group by contributing to innovation and sustainable growth. Terumo Europe produces, distributes, markets and sells a vast range of medical devices in four main business units: Hospital and Laboratory Systems, Global Pharmaceutical Solutions, Interventional Systems and Cardio Vascular Products. Terumo Europe EMEA headquarters and production facilities are located in Haasrode (Belgium), production facility in Knowsley (UK) and sales units across EMEA.
Please visit www.terumo-europe.com for more information.
About Terumo Corporation
Tokyo-based Terumo Corporation is one of the world's leading medical device manufacturers with US $6 billion in sales and operations in more than 160 nations. Founded in 1921, the company develops, manufactures, and distributes world-class medical devices including products for use in cardiothoracic surgery, interventional procedures, and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician-office use. Terumo contributes to society by providing valued products and services to the healthcare market, and by responding to the needs of healthcare providers and the people they serve. Terumo Corporation's shares are listed on the first section of the Tokyo Stock Exchange (No. 4543, Reuters symbol <4543.T>, or Bloomberg 4543: JP) and is a component of the Nikkei 225, Japan's leading stock index.
This is HCP only content